Stocks In News: Ceradyne Inc. (NASDAQ:CRDN), MMM, EXEL, ARIA

Ceradyne rises sharply on 3M takeover

Ceradyne, Inc.(NASDAQ:CRDN), which accepted 3M Co(NYSE:MMM)’s offer price of $35 per share, shot up 43 percent in pre-market trading. Shares of CRND soared 42%.

New Drug Submission in Canada pushes Apricus higher

Meanwhile, Apricus Biosciences is planning to file a New Drug Submission in Canada for the company’s topical treatment for onychomycosis, MycoVa. The Apricus stock is trading 7 percent higher in pre-market trade.

Will CRDN Continue To Move Higher? Find Out Here

Preliminary data positive for Exelisis

Pharmaceutical company Exelixis, Inc.(NASDAQ:EXEL) has said that trials have shown that even small doses of 40 milligrams of its cabozantinib drug have similar effects as large doses in reducing metastatic bone and soft tissue disease. The preliminary data of the Phase II trials were released over the weekend. The pharma company’s stock has risen 4 percent in early trade.

Positive cancer trial results push Ariad up

Another pharma company, Ariad Pharmaceuticals, Inc.(NASDAQ:ARIA) has said that the initial clinical results for AP26113, used for treating a kind of lung cancer are positive. The stock has risen 4 percent in the pre-market session. It has already risen 98 percent during the year.

Macy’s seasonal hiring to be 2.5 percent higher

Macy’s Inc plans to appoint 80,000 seasonal associates for its Macy’s and Bloomingdale’s stores. The number is 2.5 percent higher than last year’s figures of 78,000. The seasonal associates work in sales, store operations and also call centers, staff distribution and fulfillment centers for online purchases where they have telephonic interactions with customers.